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http://dx.doi.org/10.1016/j.pedneo.2Background: In April 2009, confirmed cases of influenza A (H1N1) infections were reported
worldwide, spreading from Mexico and southern California. In order to determine the clinical
features of patients infected with this virus before vaccine implementation and evaluate the
response of antiviral treatment in Taiwan, we reviewed medical charts and collected clinical
data from outpatients and inpatients at the Tao-Yuan General Hospital.
Methods: From May 19, 2009, to October 31, 2009, clinical data from patients confirmed by the
rapid antigen-screening test for influenza A virus and/or reverse transcriptaseepolymerase
chain reaction analysis at the Tao-Yuan General Hospital were reviewed retrospectively.
Results: A total of 1158 patients (94.6%) received outpatient management, 66 patients (5.4%)
were hospitalized, and no patients died. More than two-thirds of patients were younger than
16 years old. The most common symptoms were fever (99.8%), cough (91.4%), sore throat
(63.7%), and rhinorrhea (53.8%). Ninety patients (13.3%) had complications, including lower
respiratory tract infections (11.1%). Among the 677 patients receiving follow-ups, none needed
mechanical ventilation due to lower respiratory tract infection. Most of the patients (87.2%)
began antiviral therapy within 2 days after the onset of symptoms. Ninety percent of patients
became afebrile within 2 days after the initiation of antiviral therapy. The number of screening
specimens and the positivity rate of the rapid influenza A antigen test were dramatically
decreased 4 weeks later, after universal implementation of the pandemic influenza A (H1N1)
2009 vaccine to infants and school-age children.of Pediatrics, Tao-Yuan General Hospital, 1492, Chung-Shan Road, Tao-Yuan City, Tao-Yuan County
o.com.tw (C.-Y. Lee).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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258 C.-Y. Lee et alConclusion: The clinical spectrum of pandemic influenza A (H1N1) 2009 infection was broad
and the severity of disease was mild. Early antiviral treatment was effective in decreasing
mortality and morbidity. Early and universal implementation of a novel influenza A vaccine
is an effective approach for preventing pandemic community influenza outbreaks, particularly
among infants and school-age children.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The first human cases of infection with pandemic influenza
A (H1N1) 2009 (H1N1/09) were recorded in Mexico and
southern California in April 2009.1,2 This particular virus
was contagious and contained a unique genome composi-
tion that had not been identified previously in humans or
animals.3,4 The World Health Organization (WHO)
announced the emergence of the novel influenza A (H1N1)
virus on April 29, 20095 and raised the level of the influenza
pandemic alert to phase 6, its highest level, on June 11,
2009.6 During the early pandemic period (April 29, 2009,
through June 19, 2009), this novel influenza virus infection
was listed as a Category I notifiable infectious disease in
Taiwan, as it was a new and potentially serious infectious
disease.7 The first confirmed case in Taiwan was docu-
mented on May 20, 2009, at the Tao-Yuan General Hospital.
From April 29, 2009, to June 19, 2009, all suspected and
confirmed cases were treated and quarantined in hospi-
tals.7 However, spreading of H1N1/09 was considered
inevitable and, on the basis of available evidence indi-
cating that HINI/09 might cause only mild disease in
affluent countries, after June 19, 2009, H1N1/09 was no
longer considered a notifiable infectious disease in Taiwan,
except in cases of complicated infections.8 Beginning on
August 15, 2009, patients with influenza-like illnesses that
were confirmed by influenza A rapid tests were treated
with an antiviral agent (oseltamivir) offered by the Taiwan
Center for Disease Control (CDC).9 Our objectives were to
identify the clinical and epidemiologic features of patients
with H1N1/09 infections in northern Taiwan during the
pandemic period before implementation of universal
vaccination, and to evaluate the effectiveness of antiviral
therapy.2. Methods
From May 19, 2009, to October 31, 2009, data regarding
H1N1/09-infected patients were retrospectively reviewed
by well-trained infection control nurses and physicians at
the Tao-Yuan General Hospital, which is a 900-bed regional
teaching hospital. The reviewers collected data, including
demographics, contact history, travel history, underlying
medical conditions, clinical signs and symptoms, radio-
graphic findings, and treatment course. An infected H1N1/
09 patient was defined as having a positive result for the
rapid antigen screening test for influenza A virus and/or
reverse transcriptaseepolymerase chain reaction (RT-PCR)
analysis during the study period.The rapid antigen screening tests included the BD
Directigen EZ Flu AþB (Becton, Dickinson and Company,
Franklin Lakes, New Jersey, USA) and the Formosa One Sure
Flu A/B Rapid test (Formosa Biomedical Technology Corp.,
Taipei, Taiwan, R.O.C.) when there was a supply shortage
of BD Directigen EZ Flu AþB. Further confirmation by RT-
PCR assay was performed for patients hospitalized during
the period from May 5, 2009, to June 19, 2009, for patients
with complications, and for some patients as routine
sentinel surveillance during the study period. RT-PCR was
performed at laboratories operated under the auspices of
the Taiwan CDC. If subtype identification by PCR analysis
revealed H3N2 virus or seasonal H1N1 virus infection, these
data were excluded from our study.
2.1. Statistical analyses
Analyses were performed using the SPSS software package
(version 10.0, SPSS Inc., Chicago, IL, USA). Categorical vari-
ables were presented as numbers with percentages and
compared using the Chi-square or Fisher’s exact test.
Continuous variables were summarized as the
mean  standard deviation (SD) and compared using the
Mann-Whitney U test. A p value <0.05 was considered
statistically significant.
3. Results
3.1. Epidemiology and clinical features
A total of 5937 specimens were screened by influenza rapid
antigen tests at the Tao-Yuan General Hospital during the
study period. Among these, 1450 specimens (24.4%) yielded
positive influenza A rapid antigen results. The positivity
rate trend of the influenza A virus rapid antigen screening
test during the 2009 pandemic period is shown in Figure 1.
The outbreak wave began on July 19, 2009 (Pandemic Week
30), reached its peak at Week 48, and declined dramatically
thereafter. The H1N1/09 vaccine program was launched by
the Taiwan CDC on November 1, 2009 (Week 45).10 Large-
scale implementation of vaccination for school-age chil-
dren was administered from November 16, 2009 (Week
47)10 until the end of November, 2009; approximately 1.95
million people in the nation had received the H1N1/09
vaccine, and the immunization coverage rates among
infants and elementary school students had reached over
50% within 1 month.11
A total of 1228 patients’ medical records were available
for analysis, and among these, 46 (3.7%) specimens were
Figure 1 The positivity rate trend of the influenza A virus
rapid antigen-screening test at Tao-Yuan General Hospital
during the 2009 pandemic year. Beginning on August 15, 2009
(Pandemic Week 33), patients with influenza-like illnesses that
were confirmed by influenza A rapid tests were treated with an
antiviral agent (oseltamivir) offered by the Taiwan Center for
Disease Control (blue arrow). The H1N1 2009 (H1N1/09)
vaccine program was launched on November 1, 2009 (Week 45)
(red arrow).
Table 1 Characteristics and clinical features of patients
infected with pandemic influenza A (H1N1) 2009 in Northern
Taiwan.
Characteristics Value
Age, yr 16.02  13.05
(0.04e87)
Males 709 (57.9)
Contact/travel history 641 (52.4)
Underlying medical conditions 131 (10.7)
Asthma or chronic pulmonary
diseases
66 (5.4)
Hypertension 10 (0.9)
Chronic liver diseases 7 (0.6)
Neurological disorders 12 (1.0)
G6PD deficiency 16 (1.3)
Coronary heart disease 3 (0.2)
Diabetes mellitus 5 (0.4)
Neoplasm 3 (0.2)
Renal diseases 3 (0.2)
Pregnancy 4 (0.3)
Others* 7 (0.6)
Clinical features
Fever 1221 (99.8)
Cough 1120 (91.4)
Sore throat 78 (63.7)
Rhinorrhea 714 (53.8)
Headache 470 (38.4)
Myalgia 490 (40.0)
Malaise 263 (21.5)
Abdominal pain 51 (4.2)
Nausea or vomiting 137 (11.2)
Diarrhea 79 (6.5)
Chest pain or chest tightness 29 (2.4)
Data are presented as mean  SD (range) for continuous vari-
ables, and n (%) for categorical variables.
G6PD Z glucose-6-phosphate dehydrogenase.
* Including Kawasaki disease: 1; obesity: 1; systemic lupus
erythematosus: 1; phenylketonuria: 1; hyperthyroidism: 2;
arrhythmia: 1.
Figure 2 The age distribution of patients infected with
pandemic influenza A (H1N1) 2009 and the hospitalization rate
of each age group. More than two-thirds of patients were
younger than 16 years old and more than half were aged 6e15
years. Infants and elderly people older than 70 years had the
lowest rates of infection and the highest rates of
hospitalization.
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were confirmed to have H1N1/09 infections, of which four
patients were excluded because seasonal influenza A
(H3N2) infections were confirmed according to subtype
identification. A total of 1200 patients (98%) in this study
were diagnosed with H1N1/09 based on the results of rapid
antigen tests.
A total of 1158 patients (94.6%) received outpatient
management, and 66 patients (5.4%) were hospitalized.
Demographic details, clinical features, and underlying
medical conditions of these patients are listed in Table 1.
More males were affected than females (57.9% males vs.
42.1% females); the male-to-female ratio being 1.38:1. The
mean age was 16 years, with a range of 14 days to 87 years of
age. The age distribution and hospitalization rates according
to age group are shown in Figure 2; most (88.6%) of the 1224
patients were below the age of 31 years. Only 3.3% were
above 50 years of age. More than two-thirds of patients were
younger than 16 years old, and cases in the age group of 6e15
years of age comprised more than one-half (55.5%) of the
total cases. A total of 131 (10.7%) patients had one or more
underlying medical conditions, and the most common
medical condition (5.4%) was chronic pulmonary disease
(asthma or chronic obstructive pulmonary disease). Four
patients were pregnant women, and all of these patients
suffered from mild illness without mortality.
Contact and travel history were available for 641
patients (52.4%). Nine patients had recently traveled in
Taiwan within 7 days before the onset of symptoms, and 25
patients had traveled internationally to infected regions. A
total of 607 patients (49.6%) had contact history with sick
persons, with the most common exposure sites being
schools (355, 29%) and homes (225, 18.4%).
Most of the patients had fever (99.8%), cough (91.4%)
sore throat (63.7%), and rhinorrhea (53.8%). Less common
symptoms included chest pain, nausea, vomiting, abdom-
inal pain, and diarrhea. The outpatients and inpatients had
similar clinical presentations, as shown in the Table 3,
except outpatients had a higher incidence of headaches
(p Z 0.011).
Table 2 Antiviral treatment and outcomes of patients
infected with pandemic influenza A (H1N1) 2009 in Northern
Taiwan.
Antiviral treatment Value
Days from onset of symptoms
to initiation of antiviral treatment
1.64  0.90 (0e8)
Days of fever after initiation
of antiviral treatment*
1  1.20 (0e6)
Duration of fever, d* 2.74  1.64 (0e11)
Complicationsy 90 (13.3)
Bronchopneumonia 55 (8.1)
Pneumonia 13 (1.9)
Bronchiolitis 3 (0.4)
Bronchitis 2 (0.3)
Croup 2 (0.3)
Acute otitis media 2 (0.3)
Acute paranasal sinusitis 2 (0.3)
Asthma with acute exacerbation 3 (0.4)
Escherichia coli UTIz 1 (0.1)
GBS sepsisz 1 (0.1)
Hypertension 1 (0.1)
Skin rashes 2 (0.3)
Hemoptysis 2 (0.3)
Encephalitis 1 (0.1)
Data are presented as mean  SD (range) for continuous vari-
ables, and n (%) for categorical variables.
GBS Z Group B streptococcal infection; UTI Z urinary tract
infection.
* The precise clinical therapeutic responses were determined
according to the available medical records of 190 patients.
y Only 677 patients were available for analysis (66 inpatients
and 611 outpatients) because 547 patients were lost to follow-
up.
z Two patients had concurrent bacterial infections.
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Treatment and outcomes of H1N1/09 infected patients are
shown in Table 2. A total of 677 (55.3%) patients received
follow-ups, and all of the patients had become afebrile in
the subsequent follow-up. No patients died from H1N1/09
infections, and all 677 patients receiving follow-ups fully
recovered from the illness. Most (87.2%) of the patients
began antiviral therapy within 2 days after the onset of
symptoms. The mean number of days from onset of symp-
toms to initiation of antiviral treatment was 1.6 days.
However, the exact fever duration could only be accounted
for by the medical records of 190 patients (including 66
inpatients and 124 outpatients). A total of 75% of these 190
patients became afebrile within 1 day after the initiation of
antiviral therapy, and 91.4% of them became afebrile
within 2 days after treatment initiation. The mean number
of days with fever after the initiation of antiviral treatment
was 1 day; the total duration of fever was 2.7 days.
Among the 677 patients who received follow-ups
(including 66 inpatients and 611 outpatients), most
(86.7%) had mild, self-limited illness. The most common
complication was lower respiratory tract infection (11.1%),
although no patients required mechanical ventilation dueto lower respiratory tract infections. Only one patient was
admitted to the intensive care unit and received mechan-
ical ventilation due to a concurrent brain injury resulting
from a traffic accident. One patient had encephalitis,
based on the results of electronic encephalography,
without sequelae. Two patients had concurrent bacterial
infections; one had an Escherichia coli urinary tract infec-
tion and the other had group B streptococcal sepsis.
In comparison with outpatients (Table 3), the inpatients
had more underlying medical conditions, a higher compli-
cation rate, a longer duration from the onset of symptoms
to the initiation of antiviral treatment (2.14  1.48 days vs.
1.61  0.84 days; p < 0.001) and a longer duration of fever
(3.16  2.02 days vs. 2.56  1.44 days; p Z 0.023).4. Discussion
In Taiwan, the first reported case of H1N1/09 infection was
diagnosed at the Tao-Yuan General Hospital on May 20,
2009, and this patient had mild, self-limited disease.
Infection with this virus causes a broad spectrum of clinical
manifestations,12 ranging from afebrile upper respiratory
illness13 to fulminant pneumonia.14 In this study, most (87%)
of the patients had mild, self-limited illness. Similarly, self-
limited illness without fever has been reported in up to 32%
of infected cases in China.12 By contrast to that study,
a higher percentage of our patients presented with initial
fever (99.8%), since patients with influenza-like illness
were selected to undergo the rapid antigen screening test.
The clinical features among the hospitalized patients and
outpatients were similar except that the hospitalized
patients had longer fever duration.
In this study, the clinical attack rate in children was
twice as high as that in adults (<16 years of age: 66.9%; 16
years: 33%). Interestingly, high attack rates of H1N1/09
among school-age children and adolescents and relatively
low incidence of H1N1/09 infections in the elderly have
been reported elsewhere.3,15e18 It has been suggested that
children and young adults lack preexisting antibodies to
prevent viral attack, whereas the relatively low incidence
of H1N1/09 infections in the elderly population is due to
their prior exposure to a similar H1N1 strain.19e21 The
majority of our patients had self-limited respiratory
disease, with 5.4% of them hospitalized. Interestingly,
although infants and elderly patients above the age of 70 in
our study had the lowest rates of infection, they had the
highest rates of hospitalization (40%, and 25%, respectively)
if they became ill. This feature was different from the
presentation of pandemic influenza published in recent
literature reports14,15,22e24 but similar to that of seasonal
influenza.24
The incidence of hospitalization varied widely according
to country with regard to the range of estimates, from very
low rates of 2.9/100,000 population in Japan, to 24.5/
100,000 population in Argentina.25 The proportion of
hospitalized patients who required intensive care ranged
from 10% to 39%,25 whereas among 677 patients receiving
follow-ups in this study, none died of disease and only one
patient was admitted to the intensive care unit due to
a concurrent brain injury resulting from a traffic accident.
Possible explanations for the absence of deaths among
Table 3 Comparison of clinical features, treatment, and outcomes between inpatients and outpatients infected with
pandemic influenza A (H1N1) 2009.
Characteristics Inpatients (n Z 66) Outpatients (n Z 1158) p value
Age, y 15.44  18.24 16.05  12.70 0.709
Males 34 (51.5) 675 (58.3) 0.278
Symptoms
Fever 66 (100) 1155 (99.7) 0.679
Cough 59 (89.4) 1061 (91.6) 0.527
Sore throat 35 (53.0) 745 (64.3) 0.170
Rhinorrhea 39 (59.1) 675 (58.3) 0.898
Headache 14 (21.2) 456 (39.4) 0.011
Myalgia 20 (30.3) 470 (40.6) 0.243
Malaise 13 (19.7) 250 (21.6) 0.908
Abdominal pain 6 (9.1) 52 (4.5) 0.087
Vomiting 9 (13.6) 128 (11.1) 0.517
Diarrhea 6 (9.1) 73 (6.3) 0.370
Chest pain 3 (4.5) 26 (2.2) 0.232
Underlying medical conditions 15 (22.7) 116 (10.0) 0.001
Days from onset of symptoms to
initiation of antiviral treatment
2.14  1.48 1.61  0.84 0.000
Days of fever after initiation
of antiviral treatment*
1.12  1.07 0.94  1.14 0.304
Duration of fever, d* 3.16  2.02 2.56  1.44 0.023
Complications 38 (57.6) 52 (8.5)y 0.000
Data are presented as mean  SD for continuous variables, and n (%) for categorical variables.
* The precise clinical therapeutic responses were determined according to the available medical records of 190 patients, including 66
inpatients and 124 outpatients.
y Only 611 patients were included because 547 patients were lost to follow-up.
Clinical features of H1N1 261patients receiving follow-ups and the relatively positive
outcome found by our study are the early and prompt
treatment with oseltamivir and the mild virulence of this
virus. Since August 15, 2009, treatment with oseltamivir
offered by the Taiwan CDC9 has been widely provided to
patients with influenza-like illness and a positive result
from the rapid influenza A antigen test, in accordance with
recommendation from the WHO.26 All patients enrolled in
our study received a 5-day course of oseltamivir therapy as
soon as the diagnosis was established, and 87.2% of our
patients began antiviral therapy within 2 days after the
onset of illness. Early antiviral treatment was also univer-
sally implemented in Japan, and a lower mortality rate and
fewer cases of severe illness were observed as a result.27
The antiviral treatment was initiated within 48 hours
after the onset of illness in 88.9% of the hospitalized
Japanese children, and the case fatality rate was 0.1%.
Only 1.2% of the enrolled Japanese children required
mechanical ventilation. Although the characteristics of the
patients enrolled in our study and the patients in Japan
were different, the same medication policy and early,
universal implementation of antiviral treatment reduced
the disease severity and mortality in both Taiwan and
Japan, which is consistent with the previous studies
regarding seasonal influenza infection.28e31
Although universal implementation of antiviral treat-
ment was started on August 15, 2009, in Taiwan, the
number of cases of concomitant influenza-like illness and
a positive rapid antigen test result still increased (Figure 1).
This indicated that early and universal implementation ofantiviral treatment could not completely prevent the
disease from spreading in communities. According to our
study, half of the patients had contact history with sick
persons in schools or families, and more than two-thirds of
the patients were younger than 16 years of age. Therefore,
early implementation of the H1N1/09 vaccine was neces-
sary to provide the protection and herd immunity, partic-
ularly among the key targeted group: school-age children.
In Taiwan, the H1N1/09 vaccine for infants was available on
November 1, 2009 (Week 45), and large-scale imple-
mentation of vaccination for school-age children was
administered beginning November 16, 2009 (Week 47).10
The immunization coverage rates among infants and
elementary school students had both reached over 50%
within 1 month after the H1N1/09 vaccine was launched.11
The number of screening specimens and positivity rate of
the rapid influenza A antigen test dramatically decreased
after Week 48, 2009 (4 weeks after the vaccine was avail-
able). These results confirmed that the H1N1/09 vaccine
was effective in controlling the 2009 pandemic infection
when early and rapid implementation of vaccination was
administered, particularly among infants and school-aged
children.
The main limitation of this study was the problem of
diagnosis. Rapid diagnostic tests that can differentiate
between type A and type B influenza are widely used in
Taiwan, and most of our patients in this study were diag-
nosed with influenza A virus infection based on the results
of these rapid tests. We assumed that our patients had
been infected with H1N1/09 based on the surveillance data
262 C.-Y. Lee et alcollected by the Taiwan CDC. From Week 23 to Week 44 of
2009 (the weeks of the 2009 pandemic season before
vaccine implementation), 91% (2165/2379) of the influenza
A virus strains detected by the Taiwan CDC in the study
period were confirmed to be H1N1/09.32 This was the basis
for our assumption that patients diagnosed with influenza A
virus infections according to rapid diagnostic tests had
H1N1/09 infections.
Another limitation of this study was the data collection
process. Approximately 45% of our patients were lost to
follow-up; therefore, their outcomes could not be evalu-
ated. Furthermore, only 190 patients could be precisely
analyzed for the therapeutic response of antiviral treat-
ment, as the remaining patients had incomplete medical
records. These were intrinsic weak points for this retro-
spective study due to selection bias.5. Conclusions
The clinical spectrum of H1N1/09 virus infection was broad,
and the severity of disease was mild. Antiviral treatment
was effective if the antiviral therapy was administered
early to patients infected with H1N1/09. Early and
universal implementation of the H1N1/09 vaccine is an
effective approach for preventing pandemic community
influenza outbreaks, particularly among infants and school-
aged children.References
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